
    
      This is a phase 2b, multicenter, open-label, randomized, comparator-controlled clinical trial
      to evaluate the efficacy and safety of Desidustat for the management of COVID-19 patients.
      First 12 mild to moderate subjects (Test arm: Desidustat + Standard of care arm, 06 subjects
      and Reference arm: Standard of care, 06 subjects) will be enrolled in the study and after
      evaluation of safety of these 12 subjects by Data Monitoring Committee other 12 severe
      subjects (Test arm: Desidustat + Standard of care arm, 06 subjects and Reference arm:
      Standard of care arm, 06 subjects) will be enrolled in the study.
    
  